H4 Orphan Pharma

H4 Orphan Pharma is a private, clinical-stage biotech developing novel multifunctional ligands for fibrotic diseases. Its lead program targets idiopathic pulmonary fibrosis (IPF), having received positive scientific advice from the Belgian medicines agency to enter Phase 2, with a secondary program in dry eye syndrome. The company holds global patents for its platform, employs a capital-efficient R&D model, and is led by a team with strong pharmaceutical and medical expertise. Its strategy centers on addressing multifactorial orphan fibrotic conditions through compounds that act on multiple targets simultaneously.

Platform of multifunctional ligands designed to act on several biological targets simultaneously to address the multifactorial nature of fibrotic diseases.

In IPF, it competes against approved anti-fibrotics (pirfenidone, nintedanib) and a pipeline of novel mechanisms. In dry eye, it enters a large, competitive market but targets a specific inflammatory/fibrotic subset. Its differentiation is its multifunctional ligand approach, which is unique but unvalidated.